Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Pfizer Posts Street Beating Q1 Earnings, Revises FY22 Profit Outlook

  • Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50. 
  • The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion.
  • Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues.
  • Eliquis globally, up 12% operationally, driven primarily by continued increased adoption in non-valvular atrial fibrillation and oral anti-coagulant market share gains.
  • Paxlovid, COVID-19 treatment contributed $1.5 billion in global sales.
  • Prevnar sales increased 59%, driven by solid retail and wholesaler stocking of Prevnar 20 for the adult indication and favorable timing of government purchases of Prevnar 13 for the pediatric indication.
  • Chantix continues to be negatively impacted by the ongoing global pause in shipments.
  • FY22 Outlook: Pfizer reaffirms FY22 sales of $98 billion - $102 billion, below the consensus of $107.94 billion.
  • The company has revised adjusted EPS guidance to $6.25 - $6.45 from the previous guidance of $6.35 - $6.55 to include the impact of incremental acquired IPR&D.
  • Pfizer anticipates COVID-19 vaccine sales of $32 billion and around $22 billion in revenue for Paxlovid.
  • Price Action: PFE shares are down 0.64% at $48.03 during the premarket session on the last check Tuesday.
  • Image by x3 from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.